Teleflex Inc. (TFX): Price and Financial Metrics
TFX Price/Volume Stats
| Current price | $199.99 | 52-week high | $276.43 |
| Prev. close | $203.44 | 52-week low | $182.65 |
| Day low | $199.44 | Volume | 379,600 |
| Day high | $204.10 | Avg. volume | 307,805 |
| 50-day MA | $225.67 | Dividend yield | 0.67% |
| 200-day MA | $241.14 | Market Cap | 9.40B |
TFX Stock Price Chart Interactive Chart >
TFX POWR Grades
- TFX scores best on the Growth dimension, with a Growth rank ahead of 76.44% of US stocks.
- The strongest trend for TFX is in Growth, which has been heading down over the past 177 days.
- TFX's current lowest rank is in the Sentiment metric (where it is better than 17.39% of US stocks).
TFX Stock Summary
- TFX has a higher market value than 83.9% of US stocks; more precisely, its current market capitalization is $9,587,340,279.
- TELEFLEX INC's stock had its IPO on February 18, 1988, making it an older stock than 89.81% of US equities in our set.
- The volatility of TELEFLEX INC's share price is greater than that of merely 15.74% US stocks with at least 200 days of trading history.
- If you're looking for stocks that are quantitatively similar to TELEFLEX INC, a group of peers worth examining would be IART, HUN, CW, VTRS, and VNT.
- Visit TFX's SEC page to see the company's official filings. To visit the company's web site, go to www.teleflex.com.
TFX Valuation Summary
- TFX's price/sales ratio is 3.3; this is 73.68% higher than that of the median Healthcare stock.
- TFX's price/sales ratio has moved up 2.5 over the prior 243 months.
Below are key valuation metrics over time for TFX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| TFX | 2023-09-22 | 3.3 | 2.3 | 26.0 | 21.1 |
| TFX | 2023-09-21 | 3.3 | 2.3 | 25.9 | 21.1 |
| TFX | 2023-09-20 | 3.4 | 2.3 | 26.6 | 21.5 |
| TFX | 2023-09-19 | 3.4 | 2.3 | 26.8 | 21.6 |
| TFX | 2023-09-18 | 3.4 | 2.4 | 26.9 | 21.8 |
| TFX | 2023-09-15 | 3.5 | 2.4 | 27.2 | 22.0 |
TFX Growth Metrics
- Its 3 year net income to common stockholders growth rate is now at 162.86%.
- Its 4 year revenue growth rate is now at 35.29%.
- Its 4 year net cashflow from operations growth rate is now at -15.81%.
The table below shows TFX's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 2,794.959 | 445.411 | 412.629 |
| 2022-06-30 | 2,808.422 | 488.294 | 509.915 |
| 2022-03-31 | 2,817.353 | 602.851 | 487.649 |
| 2021-12-31 | 2,809.563 | 651.419 | 485.374 |
| 2021-09-30 | 2,758.828 | 645.399 | 433.426 |
| 2021-06-30 | 2,686.878 | 567.418 | 350.832 |
TFX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- TFX has a Quality Grade of C, ranking ahead of 64.94% of graded US stocks.
- TFX's asset turnover comes in at 0.39 -- ranking 117th of 186 Medical Equipment stocks.
- MDT, XRAY, and TNDM are the stocks whose asset turnover ratios are most correlated with TFX.
The table below shows TFX's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-09-26 | 0.390 | 0.549 | 0.156 |
| 2021-06-27 | 0.386 | 0.542 | 0.124 |
| 2021-03-28 | 0.369 | 0.526 | 0.103 |
| 2020-12-31 | 0.373 | 0.522 | 0.117 |
| 2020-09-27 | 0.380 | 0.534 | 0.129 |
| 2020-06-28 | 0.388 | 0.548 | 0.127 |
TFX Price Target
For more insight on analysts targets of TFX, see our TFX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $462.55 | Average Broker Recommendation | 1.5 (Moderate Buy) |
Teleflex Inc. (TFX) Company Bio
Teleflex Incorporated, headquartered in Wayne, Pennsylvania, is an American provider of specialty medical devices for a range of procedures in critical care and surgery. Teleflex has annual revenues of $2.4 billion, operations in 40 countries, and more than 12,000 employees. By 2011, the company had substantially realigned to focus on its current business as a medical-device manufacturer, having undergone several years of active acquisitions and divestitures. Teleflex has been associated with Irish corporate tax avoidance tools. Teleflex's current chief executive officer (CEO) is Liam J. Kelly, who took over from Benson F. Smith at the start of 2018; Kelly is also the company's president and former chief operating officer. (Source:Wikipedia)
Latest TFX News From Around the Web
Below are the latest news stories about TELEFLEX INC that investors may wish to consider to help them evaluate TFX as an investment opportunity.
Teleflex (TFX) Rides on Urolift Prospects Amid Cost PressuresWith respect to Teleflex's (TFX) market development objectives for UroLift, the company witnesses growth for UroLift in the hospital setting. |
Teleflex (TFX) Picked for Vizient Innovative Technology ExchangeTeleflex (TFX) gets selected to exhibit Arrow VPS Rhythm DLX Device and Arrow PICCs preloaded with the NaviCurve Stylet at the Vizient Innovative Technology Exchange. |
Teleflex (TFX) New Survey Highlights BPH Impact Life QualityTeleflex's (TFX) survey results highlight how crucial it is for men to consult a urologist if they have strange or troublesome urine symptoms. |
Teleflex Selected to Exhibit Arrow™ VPS Rhythm™ DLX Device and Arrow™ PICCs preloaded with the NaviCurve™ Stylet at Vizient Innovative Technology ExchangeWAYNE, Pa., Sept. 15, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it has been selected to exhibit Arrow™ VPS Rhythm™ DLX Device and Arrow™ PICCs preloaded with the NaviCurve™ Stylet at the Vizient Innovative Technology Exchange. Vizient, Inc., the nation’s largest provider-driven healthcare performance improvement company, will hold the Exchange on Oct. 3 in Grapevine, Texas. The annual Innovative Technology Excha |
New Survey Highlights the Quality of Life Impact of an Enlarged ProstateMen With Bothersome Urinary Symptoms Find Travel Less Enjoyable Due to Frequent Bathroom NeedsWAYNE, Pa., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced results of its new survey showing that symptoms of an enlarged prostate, also known as benign prostatic hyperplasia (BPH), can interrupt travel plans and cause other activities to be less enjoyable. Those surveyed indicated that personal plans are often dis |
TFX Price Returns
| 1-mo | -7.32% |
| 3-mo | -14.74% |
| 6-mo | -19.43% |
| 1-year | -1.54% |
| 3-year | -39.60% |
| 5-year | -22.88% |
| YTD | -19.53% |
| 2022 | -23.61% |
| 2021 | -19.89% |
| 2020 | 9.75% |
| 2019 | 46.26% |
| 2018 | 4.45% |
TFX Dividends
| Ex-Dividend Date | Type | Payout Amount | Change | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Continue Researching TFX
Want to see what other sources are saying about Teleflex Inc's financials and stock price? Try the links below:Teleflex Inc (TFX) Stock Price | Nasdaq
Teleflex Inc (TFX) Stock Quote, History and News - Yahoo Finance
Teleflex Inc (TFX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...